Tag Archives: MSB11022

March, 2016

  • 2 March

    Merck KGaA Initiates Phase 3 Study of its Humira Biosimilar

    DARMSTADT, Germany, March 2, 2016 /PRNewswire/ — Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the initiation of a global phase III clinical study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis. This milestone is a strong reflection of Merck KGaA, Darmstadt, Germany’s progress …